Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+1.60%
+0.44%
-2.20%
+1.70%
+1.48%
AZN
Astrazeneca
$85.15
Login to see Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Upgraded on attractively valued
Technical Indicators
Aroon crosses up
52-week High
Chart
$81.56 (+4.40%)
$71.13 (+19.71%)
$67.72 (+25.74%)
$78.02 (+9.14%)
AZN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
AZN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
AZN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AZN Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displayAZN Earnings
The TTM reflects 12-month period, providing review of AZN financial performance.
The company financial health has moderately improved over the past year
Financial Score
NVS
132.52
+1.18%
MRK
89.95
+0.49%
SNY
50.86
+1.46%
PFE
27.24
+0.57%
LLY
836.65
+2.05%
What is AZN current stock price?
What are AZN stock strengths?
What risks are associated with AZN stock?
When is AZN next earnings report?
What is AZN market cap and volume?
What is AZN's current Stock IQ?
Should I buy AZN stock right now?
Is AZN a Strong Buy right now?
What does a 'Strong Buy' rating mean for AZN?
What does a 'Strong Sell' rating mean for AZN?
What factors influence AZN's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.60%
+0.44%
-2.20%
+1.70%
+1.48%
AZN
Astrazeneca
Current Price
$85.15
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Upgraded on attractively valued
Technical Indicators
Aroon crosses up
52-week High
Linked to AZN
NVS
132.52
+1.18%
MRK
89.95
+0.49%
SNY
50.86
+1.46%
PFE
27.24
+0.57%
LLY
836.65
+2.05%
Login to unlock Astrazeneca (AZN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$81.56 (+4.40%)
$71.13 (+19.71%)
$67.72 (+25.74%)
$78.02 (+9.14%)
AZN Analysts Opinion
AZN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Above analyst estimates
Reported a strong earnings
Earnings increase YoY
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
AZN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
AZN Street view is extremely bullish and have positive views on the near-term outlook
AZN has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Average key support and resistance price levels.
Login to displayAZN Earnings
The TTM data reflects the most recent 12-month period, providing overview of AZN financial performance.
AZN Financial Health
The company financial health has moderately improved over the past year
Financial Score
AZN Latest Analysis
AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy?. Key PointsAstraZenecas shares jumped after Pfizers announcement of a major deal with the Trump administration.
Thu Oct 2, 2025
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term. The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why you should take advantage.
Thu Oct 2, 2025
AstraZeneca (AZN) Jumps to All-Time High on Trump Drug Tariff Delay. We recently published 10 Stocks Stealing The Spotlight Today. AstraZeneca PLC (NASDAQ:AZN) is one of the top performers on Wednesday. AstraZeneca saw its share prices jump to a new all-time high on Wednesday as investors cheered reports that President Donald Trump delayed the imposition of a 100-percent tariff on all pharmaceutical imports. A report by [….]
Thu Oct 2, 2025
Nasdaq 100 Movers: NFLX AZN. In early trading on Wednesday shares of AstraZeneca topped the list of the days best performing components of the Nasdaq 100 index trading up 6.4%. Year to date AstraZeneca registers a 24.6% gain.And the worst performing Nasdaq 100 component thus far on the day is Netflix
Wed Oct 1, 2025
AstraZeneca Daiichi win FDA review for Enhertu label expansion.
Wed Oct 1, 2025
Your AstraZeneca Medicine Could Be Cheaper As Much As 70%. ) launched AstraZeneca Direct an online platform designed to create a simple convenient way for eligible patients to access their prescribed medications at a transparent .AstraZeneca Direct will support people living with chronic conditions such as asthma diabetes heart failure and chronic kidney disease and people .Starting October 1 2025 eligible patients with prescriptions for Airsupra (albuterol/budesonide) or Farxiga (dapaglifozin)
Fri Sep 26, 2025
AstraZeneca becomes latest drugmaker to launch direct-to-consumer platform.
Fri Sep 26, 2025
AstraZeneca Announces Launch Of Online Platform AstraZeneca Direct . (RTTNews) - AstraZeneca PLC (AZN) Friday announced the launch of AstraZeneca Direct an online platform to access medications at a transparent cash price with home delivery starting October 1 2025.
Fri Sep 26, 2025
AstraZeneca to launch direct-to-patient medication platform.
Fri Sep 26, 2025
Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50 Key Companies | DelveInsight. Advanced Liver Cancer Clinical Trial Pipeline Shows Potential with Active Contributions from 50 Key Companies |. DelveInsightThe advanced liver cancer market is positioned for strong growth as rising incidence rates driven by chronic liver diseases and metabolic disorders expand the patient pool and boost demand for effective therapies. Increasing adoption of screenin
Thu Sep 25, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Latest Updates
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings